Chris Barber.

ST. LOUIS— ZeaVision Holdings, Inc., supplier of nutritional supplements for eye health, has received an equity investment from DSM Venturing, the corporate venture arm of Royal DSM, the global life sciences and material sciences company. While the company would not disclose the dollar or percentage amount of DSM’s equity investment, a ZeaVision spokesperson told VMail, “DSM is a new minority investor.”

ZeaVision president, Chris Barber, said, “DSM has a long history of excellence and innovation in the nutrition industry. We are pleased to welcome DSM as a strategic investor which offers unique potential to strengthen ZeaVision's leadership position in the ocular nutrition market.”

With more than 20 years of research and innovation, ZeaVision pioneered the use of zeaxanthin, a natural antioxidant and photo-protectant, for eye health. Its EyePromise line of nutraceuticals is formulated to help prevent age-related macular degeneration, macular edema, retinal blood vessel degeneration and dry eye.

Greg McParland, senior investment manager of DSM Venturing said, “This investment is at the core of our strategy to support emerging companies in our ecosystem and create new business opportunities. We commend ZeaVision for its innovative and science-based approach to eyecare and look forward to supporting the team in the expansion of their business.”

Will Black, vice president of marketing for DSM Nutritional Products, said, “DSM is excited to invest in the company. ZeaVision has made a significant contribution to expand research and scientific understanding of the role of nutrition in eye health.”